Form 4: Sanara MedTech Director Acquires Restricted Stock

Director Robert Andrew DeSutter acquired 3,932 shares of restricted stock in Sanara MedTech Inc. on June 12, 2024.

Summary

• On June 12, 2024, Robert Andrew DeSutter, a director of Sanara MedTech Inc., acquired 3,932 shares of common stock.
• These shares were granted as restricted stock under the company's 2014 Omnibus Long-Term Incentive Plan.
• The restricted stock will vest on June 12, 2025, contingent upon DeSutter's continued service to the company.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The stock grant is a standard practice and indicates confidence in the director's continued service and the company's future.

Positives

• The grant of restricted stock aligns the director's interests with the long-term performance of the company.
• Continued service requirement ensures commitment from the director.

Future Outlook

The vesting of the restricted stock is contingent upon the reporting person providing certain services to the Company through June 12, 2025.

Industry Context

This type of stock grant is a common practice to incentivize and retain key personnel, aligning their interests with the company's long-term success. It's typical in the biotech/medtech industry to use equity-based compensation.

Comparison to Industry Standards

• Stock grants to directors are a common practice in publicly traded companies, particularly in the medtech industry.
• Companies like Integra LifeSciences and Stryker also use stock options and restricted stock units as part of their compensation packages for directors and executives.
• The vesting period of one year is relatively standard for restricted stock grants.

Stakeholder Impact

• The stock grant aligns the director's interests with those of the shareholders.
• The vesting requirements incentivize the director to contribute to the company's success.

Key Dates